Celgene Files Pomalidomide For Myeloma In Japan
This article was originally published in PharmAsia News
Executive Summary
Celgene filed for approval of its anti-hematopoietic agent pomalidomide for the treatment of multiple myeloma in Japan on July 25, the company recently announced.